SPOTLIGHT -
Clearing Up ‘Clear Evidence’ and Implications for Labeling Post-Merck Decision
Intellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.